**Drug Utilization Review (DUR) Meeting Minutes**
**March 5, 2012**

**Members Present:** Norman Byers, John Savageau, Russ Sobotta, Cheryl Huber, Greg Pfister, Tanya Schmidt, Carrie Sorenson, Leann Ness, Jeffrey Hostetter, Todd Twogood, Carlotta McCleary, David Clinkenbeard
**Members Absent**: Kim Krohn, Steve Irsfeld, James Carlson
**Medicaid Pharmacy Department:** Brendan Joyce, Gary Betting
**HID Staff Present:** Candace Rieth

Chair, G. Pfister called the meeting to order at 1:00 pm. Chair, G. Pfister asked for a motion to approve the minutes from the December meeting. N. Byers moved that the minutes be approved and C. Huber seconded the motion. Chair, G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent.

**Budget Update**
B. Joyce informed the board members that the spending for the biennium (July-Dec data) is under budget compared to the last biennium. Rebate changes from PPACA are still being determined. The cost of brand name drugs ten years ago was approximately 73 dollars, today it is approximately 220 dollars. The cost of generic drugs ten years ago was approximately 17 dollars, today it is approximately 22 dollars. The generic rate ten years ago was 46%, today it is 80%.

**Pulmonary Arterial Hypertension Second Review**
A motion and second were made at the December meeting to place agents used to treat pulmonary arterial hypertension on prior authorization. The topic was brought up for a second review. The Revatio/Adcirca PA form will be combined with the new PAH form. There was no public comment. After discussion, Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Topical Acne Agents Second Review**
A motion and second were made at the December meeting to place Topical Acne Agents on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Cialis for Benign Prostatic Hyperplasia Second Review**
A motion and second were made at the December meeting to place Cialis for BPH on prior authorization. The topic was brought up for a second review. There was no public comment. A suggestion was made to include 'unless contraindicated' after 'patient must try and fail all alpha blockers and 5-alpha reductase inhibitors and combinations'. J. Hostetter made a motion to amend the form. G. Pfister seconded the motion. Chair, G. Pfister called for a voice vote to approve the amendment of the form. The motion passed with no audible dissent. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Combination Products Second Review**
A motion and second were made at the December meeting to place combination products that are more costly to the state than their individual ingredients on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Gralise Second Review**
A motion and second were made at the December meeting to place Gralise on prior authorization. The topic was brought up for a second review. There was no public comment. Chair, G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

**Yearly PA Review**
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Antihistamines, PPIs, COX-II/NSAIDs, Revatio, Actoplus Met, Azasite/Quixin, Carisoprodol, Blood Factors, Relistor, Sancuso, Nuvigil, and Nucynta were reviewed. Changes made:

1. Remove Allegra from antihistamine form
2. PPIs-add duration edits as an agenda item for June meeting
3. COX-II/NSAIDs-add long term utilization information as an agenda item for June meeting
4. Revatio/Adcirca will be combined with PAH form
5. Actoplus Met will be combined with combination products form
6. Merge Carisoprodol and Soma 250 form

**Lorzone Review**
B. Joyce reviewed Lorzone information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Lorzone on prior authorization with criteria of trial and failure of chlorzoxazone. J. Hostetter seconded the motion. This topic will be brought up at the next meeting for finalization.

**Provigil Review**
B. Joyce reviewed Provigil information with the Board. There was no public comment. After discussion, N. Byers made a motion to place Provigil on prior authorization for FDA approved indication. C. Sorenson seconded the motion. This topic will be brought up at the next meeting for finalization.

**Kapvay Review**
B. Joyce reviewed Kapvay information with the Board. There was no public comment. After discussion, G. Pfister made a motion to place Kapvay on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

**Dexpak/Zemapak Review**
B. Joyce reviewed Dexpak/Zemapak with the Board. There was no public comment. After discussion, T. Twogood made a motion to place Dexpak/Zemapak on prior authorization. J. Hostetter seconded the motion. This topic will be brought up at the next meeting for finalization.

**Xifaxan Review**
B. Joyce reviewed Xifaxan with the Board. There was no public comment. J. Hostetter made a motion to place Xifaxan on prior authorization for approved indication. T. Twogood seconded the motion. This topic will be brought up at the next meeting for finalization.

**Vanos Review**
B. Joyce reviewed Vanos with the Board. There was no public comment. G. Pfister made a motion to place Vanos on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

**SSRI/SNRI combination Review**
Brendan reviewed SSRI/SNRI combination information with the Board. There was no public comment. A suggestion was made that an educational letter, with a survey, be sent to prescribers of these combinations.

**Criteria Recommendations**
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. C. Huber moved to approve the new criteria and T. Twogood seconded the motion. Chair, G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held June 4, 2012. G. Hostetter made a motion to adjourn the meeting. N. Byers seconded. The motion passed with no audible dissent. Chair G. Pfister adjourned the meeting at 2:45 pm.